5‐HT2A and D2 receptor blockade increases cortical DA release via 5‐HT1A receptor activation: a possible mechanism of atypical antipsychotic‐induced cortical dopamine release
暂无分享,去创建一个
H. Meltzer | S. Bonaccorso | H Y Meltzer | J. Ichikawa | I. O'Laughlin | W. L. Fowler | J Ichikawa | H Ishii | S Bonaccorso | W L Fowler | I A O'Laughlin | Hideo Ishii | Ian A. O'Laughlin
[1] J. Arnt,et al. Do Novel Antipsychotics Have Similar Pharmacological Characteristics? A Review of the Evidence , 1998, Neuropsychopharmacology.
[2] H. Meltzer,et al. Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors. , 1993, The Journal of pharmacology and experimental therapeutics.
[3] D. Goff,et al. An open trial of buspirone added to neuroleptics in schizophrenic patients. , 1991, Journal of clinical psychopharmacology.
[4] D. Wong,et al. Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum , 1998, Psychopharmacology.
[5] L. Adler,et al. Effects of buspirone in seven schizophrenic subjects. , 1990, Journal of clinical psychopharmacology.
[6] K. Perry,et al. The Potent, Selective mGlu2/3 Receptor Agonist LY379268 Increases Extracellular Levels of Dopamine, 3,4‐Dihydroxyphenylacetic Acid, Homovanillic Acid, and 5‐Hydroxyindole‐3‐Acetic Acid in the Medial Prefrontal Cortex of the Freely Moving Rat , 2000, Journal of neurochemistry.
[7] H. Meltzer,et al. The effect of serotonin1A receptor agonism on antipsychotic drug-induced dopamine release in rat striatum and nucleus accumbens , 2000, Brain Research.
[8] Antagonist properties of LY 165,163 at pre- and postsynaptic dopamine D2, D3 and D1 receptors: modulation of agonist actions at 5-HT1A receptors in vivo. , 1995, The Journal of pharmacology and experimental therapeutics.
[9] Anne W. Schmidt,et al. 5-HT1A receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex , 2000, Biological Psychiatry.
[10] T. Sharp,et al. Behavioural evidence for a functional interaction between central 5‐HT2 and 5‐HT1A receptors , 1990, British journal of pharmacology.
[11] F. Bymaster,et al. The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors , 1999, Psychopharmacology.
[12] C. Tanaka,et al. Regulation of GABA release via NMDA and 5-HT1A receptors in guinea pig dentate gyrus , 1996, Brain Research.
[13] Philip Seeman,et al. Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine , 1996, Neuropsychopharmacology.
[14] H. Meltzer,et al. Direct injection of 5-HT2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats. , 1997, The Journal of pharmacology and experimental therapeutics.
[15] C. Tanaka,et al. Regulation of glutamate release via NMDA and 5-HT1A receptors in guinea pig dentate gyrus , 1996, Brain Research.
[16] M. Millan,et al. Serotonin (5-HT)2A receptor activation enhances dialysate levels of dopamine and noradrenaline, but not 5-HT, in the frontal cortex of freely-moving rats , 1999, Neuropharmacology.
[17] Anne W. Schmidt,et al. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. , 1995, The Journal of pharmacology and experimental therapeutics.
[18] K. Young,et al. Enhancement of antipsychoticlike properties of raclopride in rats using the selective serotonin2A receptor antagonist MDL 100,907 , 1998, Biological Psychiatry.
[19] B. Moghaddam,et al. Actions of clozapine and haloperidol on the extracellular levels of excitatory amino acids in the prefrontal cortex and striatum of conscious rats , 1993, Neuroscience Letters.
[20] A. Baba,et al. Postsynaptic 5‐hydroxytryptamine1A receptor activation increases in vivo dopamine release in rat prefrontal cortex , 2000, British journal of pharmacology.
[21] E. Esposito,et al. Serotonin-dopamine interaction in the rat ventral tegmental area: an electrophysiological study in vivo. , 1994, The Journal of pharmacology and experimental therapeutics.
[22] L. Swanson. The Rat Brain in Stereotaxic Coordinates, George Paxinos, Charles Watson (Eds.). Academic Press, San Diego, CA (1982), vii + 153, $35.00, ISBN: 0 125 47620 5 , 1984 .
[23] T. Svensson,et al. Enhancement of antipsychotic-like properties of the dopamine D2 receptor antagonist, raclopride, by the additional treatment with the 5-HT2 receptor blocking agent, ritanserin, in the rat , 1996, European Neuropsychopharmacology.
[24] M. Millan,et al. Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a []GTPγS binding study , 1998 .
[25] R. Andrade,et al. 5-Hydroxytryptamine2 and 5-hydroxytryptamine1A receptors mediate opposing responses on membrane excitability in rat association cortex , 1991, Neuroscience.
[26] T. Matsuda,et al. Novel benzodioxan derivative, 5-(3-[((2S)-1,4-benzodioxan-2- ylmethyl)amino]propoxy)-1,3-benzodioxole HCl (MKC-242), with a highly potent and selective agonist activity at rat central serotonin1A receptors. , 1995, Japanese journal of pharmacology.
[27] H. Meltzer,et al. R(+)-8-OH-DPAT, a 5-HT1A receptor agonist, inhibits amphetamine-induced serotonin and dopamine release in rat medial prefrontal cortex , 1996, Brain Research.
[28] H. Meltzer,et al. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. , 1989, The Journal of pharmacology and experimental therapeutics.
[29] M. Santiago,et al. The regulation of dopamine release from nigrostriatal neurons in conscious rats: the role of somatodendritic autoreceptors. , 1991, European journal of pharmacology.
[30] H. Meltzer,et al. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. , 1999, Schizophrenia bulletin.
[31] F. Borsini,et al. BIMG 80, a Novel Potential Antipsychotic Drug: Evidence for Multireceptor Actions and Preferential Release of Dopamine in Prefrontal Cortex , 1997, Journal of neurochemistry.
[32] H. Meltzer,et al. Effect of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens. , 1998, European journal of pharmacology.
[33] M. Millan,et al. Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto- and heteroreceptor-mediated control of release , 1998, Neuroscience.
[34] J. Palacios,et al. Quantitative autoradiographic mapping of serotonin receptors in the rat brain. II. Serotonin-2 receptors , 1985, Brain Research.
[35] B. Westerink,et al. Characterization and Pharmacological Responsiveness of Dopamine Release Recorded by Microdialysis in the Substantia Nigra of Conscious Rats , 1991, Journal of neurochemistry.
[36] Anne W. Schmidt,et al. Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. , 1997, European journal of pharmacology.
[37] T. Svensson,et al. Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha2 adrenoceptor blockade. , 1999, Science.
[38] H. Meltzer,et al. Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs , 1999, European Archives of Psychiatry and Clinical Neuroscience.
[39] B. Bunney,et al. Acute Effects of Typical and Atypical Antipsychotic Drugs on the Release of Dopamine from Prefrontal Cortex, Nucleus Accumbens, and Striatum of the Rat: An In Vivo Microdialysis Study , 1990, Journal of neurochemistry.
[40] M. Minchin,et al. Characterisation of the Binding of [3H]WAY‐100635, a Novel 5‐Hydroxytryptamine1A Receptor Antagonist, to Rat Brain , 1995, Journal of neurochemistry.
[41] H. Meltzer,et al. Effect of adjunctive treatment with serotonin-1A agonist tandospirone on memory functions in schizophrenia. , 2000, Journal of clinical psychopharmacology.
[42] R. Glennon,et al. Binding of phenylalkylamine derivatives at 5-HT1C and 5-HT2 serotonin receptors: evidence for a lack of selectivity. , 1992, Journal of medicinal chemistry.
[43] J. Palacios,et al. Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I. Serotonin-1 receptors , 1985, Brain Research.
[44] H. Meltzer,et al. R(+)-8-OH-DPAT, a serotonin(1A) receptor agonist, potentiated S(-)-sulpiride-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens but not striatum. , 1999, The Journal of pharmacology and experimental therapeutics.
[45] H. Meltzer,et al. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. , 1999, The Journal of pharmacology and experimental therapeutics.
[46] T. Svensson,et al. Risperidone inhibits 5‐hydroxytryptaminergic neuronal activity in the dorsal raphe nucleus by local release of 5‐hydroxytryptamine , 1997, British journal of pharmacology.
[47] Rex Y. Wang,et al. Electrophysiological evidence for a functional interaction between 5‐HT1A and 5‐HT2A receptors in the rat medial prefrontal cortex: An lontophoretic study , 1994, Synapse.
[48] INTERNATIONAL SOCIETY FOR NEUROCHEMISTRY , 1976 .
[49] H. Tanaka,et al. Interaction of SM-3997 with serotonin receptors in rat brain. , 1988, Japanese journal of pharmacology.
[50] M. Millan,et al. Interactions of (+)- and (-)-8- and 7-hydroxy-2-(di-n-propylamino)tetralin at human (h)D3, hD2 and h serotonin1A receptors and their modulation of the activity of serotoninergic and dopaminergic neurones in rats. , 1997, The Journal of pharmacology and experimental therapeutics.
[51] M. Pompeiano,et al. Distribution and cellular localization of mRNA coding for 5-HT1A receptor in the rat brain: correlation with receptor binding , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.